Catalyst
Slingshot members are tracking this event:
Opko (OPK) commenced study of its Claros POC diagnostic test for prostate specific antigen (PSA), with FDA application expected mid-2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| OPK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2017
Occurred Source:
http://investor.opko.com/releasedetail.cfm?ReleaseID=1047471
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Poc Diagnostic Test, Prostate Specific Antigen, Fda Review
